Skip to content

US · TECX · BIOTECHNOLOGY

Tectonic Therapeutic, Inc. (TECX) intrinsic value and stock valuation

$20.73as of 2026-11-21 · Mkt cap 557.77M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tectonic Therapeutic, Inc. DCF and intrinsic value

InvestorsCraft values TECX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TECX’s statements →

Tectonic Therapeutic, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 tectonictx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-74.15M
20162025
Free cash flow
-$-60.29M
20162025
Total equity
$251.3M-0.2% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-84.04M-$-58.02M-$-44.65M-$-32.83M-$-15.61M
Net income-$-74.15M-$-57.98M-$-42.82M-$-32.18M-$-8.93M
EPSd-$-4.05M-$-3.93M-$-11.54M-$-8.84M-$-2.5M
Operating cash flow-$-60.08M-$-59.08M-$-40.68M-$-97.21M-$-12.45M
Capital expenditure-$-210K-$-160K-$-280K-$-270K-$-2.12M
Free cash flow-$-60.29M-$-59.24M-$-40.96M-$-97.47M-$-14.58M
Total assets$261M$152.9M$39.4M$47.2M$32.9M
Total debt$1.28M$3.3M$4.34M$5.79M$1.05M
Net debt-$-252.52M-$-137.94M-$-24.43M-$-30.17M-$-27.01M
Total equity$251.3M$140.8M-$-84.64M-$-45.65M-$-14.96M
Cash and short-term investments$253.8M$141.2M$28.8M$36M$28.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$63.5M$41.4M$37M$25.7M$11M
Selling, general and administrative expenses$20.6M$16.7M$7.68M$7.18M$4.63M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$84M$58M$44.7M$32.8M$15.6M
Cost and expenses$84M$58M$44.7M$32.8M$15.6M
Interest income$11.3M$4.26M$580K$150K$0.00
Interest expense$60K$110K$150K$140K$220K
Depreciation and amortization$1.38M$1.65M$1.48M$1.01M$360K
Ebitda-$-71.48M-$-56.23M-$-41.19M-$-31.03M-$-8.12M
Operating income-$-84.04M-$-58.02M-$-44.65M-$-32.83M-$-15.61M
Total other income/expenses, net$11.1M$30K$1.82M$650K$6.68M
Income before tax-$-72.92M-$-57.98M-$-42.82M-$-32.18M-$-8.93M
Income tax expense$1.23M$0.00$0.00$0.00$0.00
Net income-$-74.15M-$-57.98M-$-42.82M-$-32.18M-$-8.93M
Weighted average shares outstanding$18.3M$14.8M$3.69M$3.64M$3.57M
Weighted average diluted shares outstanding$18.3M$14.8M$3.71M$3.64M$3.57M
Balance sheet
20252024202320222021
Cash and short-term investments$253.8M$141.2M$28.8M$36M$28.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$257.4M$146.9M$30.9M$37M$28.6M
Property, plant and equipment, net$2.55M$5.3M$7.23M$9.55M$3.66M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$590K$0.00$0.00$0.00
Total non-current assets$3.68M$6.05M$8.52M$10.2M$4.26M
Total assets$261M$152.9M$39.4M$47.2M$32.9M
Accounts payable$1.09M$980K$410K$570K$1.81M
Short-term debt$1.23M$2.78M$1.82M$1.45M$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.67M$11.6M$40.9M$7.84M$4.12M
Long-term debt$40K$520K$2.52M$4.34M$700K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$40K$520K$83.2M$85M$43.7M
Capital lease obligations$1.23M$3.3M$4.34M$5.79M$1.05M
Total liabilities$9.71M$12.1M$124M$92.9M$47.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-222.74M-$-148.59M-$-90.6M-$-47.78M-$-15.6M
Accumulated other comprehensive income (loss)-$-100K$10K-$-10K$0.00$0.00
Total equity$251.3M$140.8M-$-84.64M-$-45.65M-$-14.96M
Total investments$0.00$590K$0.00$0.00$0.00
Total debt$1.28M$3.3M$4.34M$5.79M$1.05M
Net debt-$-252.52M-$-137.94M-$-24.43M-$-30.17M-$-27.01M
Cash flow statement
20252024202320222021
Net income-$-74.15M-$-57.98M-$-42.82M-$-30K-$-8.93M
Depreciation and amortization$1.38M$1.65M$1.48M$0.00$360K
Stock-based compensation$10.5M$3.49M$1.12M$0.00$640K
Change in working capital-$-70K-$-10.28M-$-580K-$-7.4M$1.92M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$120K-$-1.42M-$-170K-$-3.1M$1.45M
Net cash provided by operating activities-$-60.08M-$-59.08M-$-40.68M-$-97.21M-$-12.45M
Investments in property, plant and equipment-$-210K-$-160K-$-280K-$-270K-$-2.12M
Acquisitions, net$70K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-140K-$-160K-$-280K-$-270K-$-2.12M
Common stock issued$174.3M$94.6M$34.1M$260K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$173.4M$171.7M$33.8M$260K$41.4M
Net change in cash$113M$112.5M-$-7.2M-$-96.72M$26.8M
Cash at end of period$254.9M$141.8M$29.4M$92.9M$28.7M
Operating cash flow-$-60.08M-$-59.08M-$-40.68M-$-97.21M-$-12.45M
Capital expenditure-$-210K-$-160K-$-280K-$-270K-$-2.12M
Free cash flow-$-60.29M-$-59.24M-$-40.96M-$-97.47M-$-14.58M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tectonic Therapeutic, Inc.

        Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

        CEO
        Alise S. Reicin
        Employees
        60
        Beta
        0.22

        Explore

        Frequently asked questions

        What is the intrinsic value of Tectonic Therapeutic, Inc. (TECX)?

        InvestorsCraft does not currently publish an intrinsic value for TECX. How the IC value is calculated.

        Is TECX undervalued?

        InvestorsCraft does not publish an undervaluation signal for TECX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.